Two stocks in Healthcare
Eurofins Scientific vs UCB: profit, growth, debt and price compared
UCB is stronger on 5 of 7 figures: profit margin, sales growth, debt, analysts' view and price trend. Eurofins Scientific is stronger on 2: price for its expected profit and dividend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Eurofins ScientificERF.PA | UCBUCB.BR | |
|---|---|---|
| Net margin | 7.2% | Stronger: 25.7% |
| Revenue growth, past year | +2.50% | Stronger: +22.50% |
| Debt to equity | 96.1% | Stronger: 30.8% |
| Forward P/E | Stronger: 17.9× | 19.1× |
| Dividend yield | Stronger: 0.82% | 0.51% |
| Analysts | Hold · 14 | Stronger: Buy · 19 |
| From its 200-day average | +18.5% | Stronger: +19.9% |
Share price over the past year
- Eurofins Scientific+45.4%
- UCB+20.8%
24 Nov 202518 Nov 2026
Eurofins Scientific or UCB: which is stronger?
- UCB.BR
Which is more profitable?
UCB keeps more of each sale as profit: 25.7% against 7.2%.
- UCB.BR
Which is growing its sales faster?
UCB is growing its sales faster: +22.50% over the past year, against +2.50%.
- UCB.BR
Which has borrowed less?
UCB has borrowed less: its debt is 30.8% of what its shareholders own, against 96.1% for Eurofins Scientific.
- ERF.PA
Which costs less for the profit it is expected to make?
Eurofins Scientific costs less for the profit it is expected to make: 17.9× its forward earnings, against 19.1×.
- ERF.PA
Which pays more in dividends?
Eurofins Scientific pays more back in dividends for what a share costs: 0.82% a year, against 0.51%.
- UCB.BR
Which do analysts rate higher?
Analysts are warmer on UCB: Buy, against Hold for Eurofins Scientific.
- UCB.BR
Which is in the stronger price trend?
UCB's price is in the stronger trend: 19.9% above its 200-day average, against 18.5% above.
What each company does
ERF.PAEurofins Scientific
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide.
Reports results on 28 January 2027
UCB.BRUCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Reports results on 25 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.